- Home
- GERN vs DNTH Comparison
GERN vs DNTH Comparison
Compare GERN & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GERN
- DNTH
- Stock Information
- Founded
- GERN 1990
- DNTH 2015
- Country
- GERN United States
- DNTH United States
- Employees
- GERN N/A
- DNTH N/A
- Industry
- GERN Biotechnology: Pharmaceutical Preparations
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- GERN Health Care
- DNTH Health Care
- Exchange
- GERN Nasdaq
- DNTH Nasdaq
- Market Cap
- GERN 700.6M
- DNTH 651.8M
- IPO Year
- GERN 1996
- DNTH N/A
- Fundamental
- Price
- GERN $1.46
- DNTH $24.30
- Analyst Decision
- GERN Buy
- DNTH Strong Buy
- Analyst Count
- GERN 8
- DNTH 8
- Target Price
- GERN $3.71
- DNTH $54.00
- AVG Volume (30 Days)
- GERN 12.0M
- DNTH 362.9K
- Earning Date
- GERN 08-06-2025
- DNTH 08-07-2025
- Dividend Yield
- GERN N/A
- DNTH N/A
- EPS Growth
- GERN N/A
- DNTH N/A
- EPS
- GERN N/A
- DNTH N/A
- Revenue
- GERN $164,447,000.00
- DNTH $4,854,000.00
- Revenue This Year
- GERN $159.14
- DNTH N/A
- Revenue Next Year
- GERN $52.76
- DNTH N/A
- P/E Ratio
- GERN N/A
- DNTH N/A
- Revenue Growth
- GERN 11877.20
- DNTH 17.87
- 52 Week Low
- GERN $1.09
- DNTH $13.37
- 52 Week High
- GERN $4.83
- DNTH $32.27
- Technical
- Relative Strength Index (RSI)
- GERN 59.63
- DNTH 69.50
- Support Level
- GERN $1.26
- DNTH $19.84
- Resistance Level
- GERN $1.55
- DNTH $21.18
- Average True Range (ATR)
- GERN 0.09
- DNTH 1.58
- MACD
- GERN 0.02
- DNTH 0.39
- Stochastic Oscillator
- GERN 75.00
- DNTH 89.88
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.